Ocular Therapeutix (NasdaqGM:OCUL) Update / briefing Transcript

Ocular Therapeutix (NasdaqGM:OCUL) Update / briefing March 02, 2026 07:30 AM ET Company ParticipantsArshad Khanani - Director of Clinical ResearchBill Slattery Jr. - VP of Investor RelationsDarius M. Moshfeghi - Rescue Monitor in SOL-1 trial and Chief of Retina DivisionJeff Heier - Chief Scientific OfficerLisa Walter - VP of Biotech Equity ResearchPeter Kaiser - Chief Development OfficerPravin U. Dugel - Executive Chairman, President, and CEOTazeen Ahmad - Managing Director in U.S. Equity ResearchYi Chen - ...